Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma

Andy Karabajakian; Thibaut Garrivier; Carole Crozes; Nicolas Gadot; Jean-Yves Blay; Frédéric Bérard; Philippe Céruse; Philippe Zrounba; Pierre Saintigny; Charles Mastier; Jérôme Fayette

doi:10.18632/oncotarget.28316

Oncotarget

On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Learn more.

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma

PDF | How to cite

Oncotarget. 2022; 13:1305-1305. https://doi.org/10.18632/oncotarget.28316

Metrics: PDF 557 views | ?

Andy Karabajakian¹, Thibaut Garrivier², Carole Crozes³, Nicolas Gadot⁴, Jean-Yves Blay¹, Frédéric Bérard⁵, Philippe Céruse⁶, Philippe Zrounba⁷, Pierre Saintigny⁴, Charles Mastier² and Jérôme Fayette¹

¹Department of Medical Oncology, Centre Léon Bérard, Lyon, France
²Department of Radiology, Centre Léon Bérard, Lyon, France
³Department of Pathology, Centre Léon Bérard, Lyon, France
⁴Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France
⁵Department of Allergology and Clinical Immunology, CHU Lyon-Sud, Pierre-Bénite, France
⁶Department of Head and Neck Surgery, Hôpital Universitaire de la Croix-Rousse, Lyon, France
⁷Department of Medical Oncology, Centre Léon Bérard, Lyon, France

Published: December 06, 2022

Copyright: © 2022 Karabajakian et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Patient consent was obtained from the patient. This study was approved by the ethical review board of Centre Léon-Bérard.

Original article: Oncotarget. 2020; 11:1618–1628. DOI: https://doi.org/10.18632/oncotarget.27563

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28316

Announcements

Publication Alerts

Addendum:

Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma